Etofibrate
Systematic (IUPAC) name | |
---|---|
2-[(pyridin-3-yl)carbonyloxy]ethyl 2-(4-chlorophenoxy)-2-methylpropanoate | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pharmacokinetic data | |
Metabolism | Hydrolyzed to clofibric acid and niacin |
Identifiers | |
CAS Number | 31637-97-5 |
ATC code | C10AB09 (WHO) |
PubChem | CID 65777 |
DrugBank | DB08983 |
ChemSpider | 59197 |
UNII | 23TF67G79M |
KEGG | D07187 |
ChEMBL | CHEMBL358150 |
Chemical data | |
Formula | C18H18ClNO5 |
Molar mass | 363.792 g/mol |
| |
| |
(verify) |
Etofibrate is a fibrate. It is a combination of clofibrate and niacin, linked together by an ester bond. In the body, clofibrate and niacin separate and are released gradually, in a manner similar to controlled-release formulations.[1]
References
- ↑ Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA (2001). "Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects". Braz J Med Biol Res 34 (2): 177–82. doi:10.1590/S0100-879X2001000200004. PMID 11175492. Free full text
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.